Attention-based deep learning quantifies right ventricular volume from 2D echocardiography, enabling affordable, accurate, accessible cardiac assessment.

BBB-nonpermeable SIGMAR1 agonists MY33-1/2 treat Timothy Syndrome, reducing cardiac arrhythmias via targeted stem-cell model rescue.

Patient-derived iPSC heart tissue model reproduces FLNC-linked RCM for drug screening and therapy discovery.

Small-molecule protein therapy boosts cardiac contractility by raising calcium without increasing heart rate, reducing tachycardia risk.

Ubiquinone-based anesthetic with safe, controllable, reversible sedation; minimal side effects, suitable for diverse patient groups.

Continuous, self-calibrating cuffless wrist monitor enables real-time, non-invasive blood pressure tracking with movement correction.

Deep-learning desktop GUI automating multimodal cardiac tissue video analysis for high-throughput drug screening and phenotyping.

Recombinant FSTL-1 protein targets and reduces cardiac inflammation, aiding Kawasaki disease research and myocarditis treatment.

Inducible mouse model to disrupt TRIP8b, altering HCN ion channel localization in heart/brain cells for in vivo study and drug screening.

Hybrid digital health platform shifts cardiac rehab home-based with telehealth, remote monitoring, and real-time EHR integration.

Intracardiac echocardiography enables real-time visualization and classification of ablation lesions, reducing repeat procedures.

Non-invasive engineered human heart tissue platform diagnosing myocarditis via serum-induced contractility and calcium handling changes.

Inducible cardiac NRROS-based NOX2 inhibition in mice; tissue-specific ROS control to protect against diet-induced arrhythmias.

FixR uses a cell-targeted peptide to more selectively block late cardiac sodium currents, reducing arrhythmia risk.

AI-powered ECG screening detects aortic stenosis and valve regurgitation early, enabling cost-effective, population-wide diagnosis.